Wrap Text
Listing Rule 9.2.6E Confirmation (Disclosure of rights attached to equity shares)
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")
24 April 2020
Listing Rule 9.2.6E Confirmation
(Disclosure of rights attached to equity shares)
In accordance with paragraph 9.2.6E (disclosure of rights attached to equity shares) of the
Listing Rules of the Financial Conduct Authority (the "FCA"), which comes into effect on 27 April
2020, the Company has today forwarded to the FCA for publication on the National Storage
Mechanism ("NSM") a document setting out the changes which have occurred in relation to the
rights attached to the Company’s listed equity shares since the publication of its prospectus on
19 November 2015 (the "Prospectus"), namely the redemption of the 50,000 redeemable non-
voting preference shares of £1.00 and the repurchase and cancellation of the 10 subscriber
shares of £0.10 each, as anticipated in the Prospectus, which were completed in 2016.
There have been no changes to the rights attached to the ordinary shares of the Company
since the publication of the Prospectus.
The NSM can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United
Arab Emirates.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
Mediclinic comprises 77 hospitals, five sub-acute hospitals, 15 day case clinics and 22
outpatient clinics. Hirslanden operates 17 hospitals, three day case clinics and three outpatient
clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations
include 53 hospitals (three of which in Namibia), five sub-acute hospitals and 10 day case clinics
(four of which are operated by Intercare) across South Africa, and more than 8 500 inpatient
beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 19
outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.
The Company’s primary listing is on the London Stock Exchange ("LSE") in the United Kingdom,
with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in
Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 24-04-2020 05:15:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
